Federal Register / Vol. 86, No. 114 / Wednesday, June 16, 2021 / Notices 32049 

49HHS/CDC. Guidance Regarding Agency 

Interpretation of ‘‘Rabies-Free’’ as It Relates to the 

Importation of Dogs Into the United States. (January 

31, 2019) 84 FR 724: 724–730. 

50HHS/CDC. Guidance Regarding Agency 

Interpretation of ‘‘Rabies-Free’’ as It Relates to the 

Importation of Dogs Into the United States. (January 

31, 2019) 84 FR 724: 724–730. 

51Bureau of Labor Statistics, May 2019 National 

Occupational Employment and Wage Estimates. 

https://www.bls.gov/oes/current/oes_nat.htm. 

52Bureau of Labor Statistics in the May 2019 

National Occupational Employment and Wage 

Estimates United States https://www.bls.gov/oes/ 

current/oes_nat.htm. 

53Rayburn et al. (2020) Rabies in a Dog Imported 

from Egypt—Kansas, 2019. MMWR; 69(38): 1374– 

1377. 

54HHS/CDC. Guidance Regarding Agency 

Interpretation of ‘‘Rabies-Free’’ as It Relates to the 

Importation of Dogs Into the United States. (January 

31, 2019) 84 FR 724: 724–730. 

55Rayburn et al. (2020) Rabies in a Dog Imported 

from Egypt—Kansas, 2019. MMWR; 69(38): 1374– 

1377. 

56HHS/CDC. Guidance Regarding Agency 

Interpretation of ‘‘Rabies-Free’’ as It Relates to the 

Importation of Dogs Into the United States. (January 

31, 2019) 84 FR 724: 724–730. 

• An assumed cost of $600 per dog 

for airlines to fly abandoned dogs back 

to their countries of origin.49

The costs associated with an 

importation of a dog with CRVV 

includes health department staff time 

for the public health response, 

payments for post-exposure prophylaxis 

treatment for exposed persons, and the 

costs associated with quarantining or 

euthanizing exposed animals. CDC 

estimated the response cost per 

imported dog with CRVV to be 

$315,682, range $215,386 to $508,879 

based on the following assumptions: 

• An estimate of 800 hours of health 

department staff time per importation.50

• The public health response time is 

split evenly among veterinarians (code 

29–1131, $50.39 per hour), 

epidemiologists (19–1041, $37.64 per 

hour), registered nurses (29–1141, 

$37.24 per hour), licensed practical 

nurses (29–2061, $23.32 per hour), and 

office and administrative assistants (43– 

0000, $19.73 per hour).51 52 These wage 

estimates are multiplied by 2 to account 

for non-wage benefits and overhead. 

• An average of 25 (range: 16–44) 

individuals will require post-exposure 

prophylaxis because of exposure to the 

dog with CRVV.53 54

• The average cost of post-exposure 

prophylaxis was estimated to be 

$9,290.55

• An estimated 29.6 animals would 

need to be quarantined or euthanized 

due to exposure to the dog with CRVV. 

• Each exposed animal would incur 

economic costs of $1,000 for quarantine 

or euthanasia.56

V. Terms of This Notice 

Therefore, pursuant to 42 CFR 

71.51(e) and 42 CFR 71.63, and subject 

to the terms of this notice, CDC hereby 

excludes the entry and suspends the 

importation of dogs from high-risk 

countries, including dogs from low-risk 

and CRVV-free countries if the dogs 

have been present in a high-risk country 

in the previous six months. 

Additionally, under 42 CFR 71.63, 

CDC finds that CRVV exists in countries 

designated as high-risk countries and 

that, if reintroduced into the United 

States, CRVV would threaten the public 

health of the United States. The 

continued entry of dogs from high-risk 

countries in the context of the current 

limited CDC resources and personnel 

diverted to respond to COVID–19 

further increases the risk that CRVV 

may be introduced, transmitted, or 

spread into the United States. CDC has 

coordinated in advance with other 

federal agencies as necessary to 

implement and enforce this notice. 

This notice is not a rule within the 

meaning of the Administrative 

Procedure Act (‘‘APA’’), but rather 

notice of an emergency action taken 

under the existing authority of 42 CFR 

71.51(e) and 42 CFR 71.63. In the event 

that this notice qualifies as a rule under 

the APA, notice and comment and a 

delay in effective date are not required 

because there is good cause to dispense 

with prior public notice and the 

opportunity to comment on this notice. 

Considering the public health 

emergency caused by the virus 

associated with COVID–19, the ongoing 

diversion of public health resources and 

personnel to respond to the pandemic, 

and the risk of reintroduction of CRVV 

from dogs being imported from high-risk 

countries, it would be impractical and 

contrary to the public’s health, and by 

extension the public’s interest, to delay 

the issuance and effective date of this 

notice. 

Effective July 14, 2021: Pursuant to 

the exception, dogs from high riskcountries must be 6 months of age to be 

imported and fully vaccinated against 

rabies, and eligible importers may only 

import up to 3 dogs upon receipt of 

advanced written approval from the 

CDC. Importers wishing to import dogs 

from high-risk countries should: 

1. Submit a request for advanced 

written permission (i.e., Application for 

a Permit to Import a Dog Inadequately 

Immunized Against Rabies, (approved 

under OMB Control Number 0920–0134 

Foreign Quarantine Regulations (exp. 

03/31/2022), or as revised)) at least 30 

days prior to planned importation in the 

United States. 

2. Submit all documentation listed 

above in Section III Advanced Written 

Approval. 

The request for advance written 

permission must include proof of the 

dog’s identity including pictures of the 

dogs’ teeth, other descriptive details, 

proof of rabies vaccination, and 

microchip information. Dogs arriving 

from high-risk countries must enter the 

United States at a port of entry with a 

live animal care facility with a CBPissued FIRMS code that can provide 

accommodation that meets the U.S 

Department of Agriculture’s Animal 

Welfare Act standards. 

This temporary suspension will 

remain in place until the earliest of (1) 

the expiration of the Secretary of Health 

and Human Services’ declaration that 

COVID–19 constitutes a public health 

emergency; (2) the CDC Director 

rescinds or modifies this suspension 

based on specific public health or other 

considerations; or (3) 360 days from 

publication in the Federal Register. 

Dated: June 9, 2021. 

Sandra Cashman, 

Executive Secretary, Centers for Disease 

Control and Prevention. 

[FR Doc. 2021–12418 Filed 6–14–21; 4:15 pm] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifier: CMS–10494 and CMS– 

10773] 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services, Health and Human 

Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Medicare & 

Medicaid Services (CMS) is announcing 

an opportunity for the public to 

comment on CMS’ intention to collect 

information from the public. Under the 

Paperwork Reduction Act of 1995 (the 

PRA), federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information (including each proposed 

extension or reinstatement of an existing 

collection of information) and to allow 

60 days for public comment on the 

proposed action. Interested persons are 

invited to send comments regarding our 

burden estimates or any other aspect of 

this collection of information, including 

the necessity and utility of the proposed 


jbell on DSKJLSW7X2PROD with NOTICES
32050 Federal Register / Vol. 86, No. 114 / Wednesday, June 16, 2021 / Notices 

information collection for the proper 

performance of the agency’s functions, 

the accuracy of the estimated burden, 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected, and the use of automated 

collection techniques or other forms of 

information technology to minimize the 

information collection burden. 

DATES: Comments must be received by 

August 16, 2021. 

ADDRESSES: When commenting, please 

reference the document identifier or 

OMB control number. To be assured 

consideration, comments and 

recommendations must be submitted in 

any one of the following ways: 

1. Electronically. You may send your 

comments electronically to http://

www.regulations.gov. Follow the 

instructions for ‘‘Comment or 

Submission’’ or ‘‘More Search Options’’ 

to find the information collection 

document(s) that are accepting 

comments. 

2. By regular mail. You may mail 

written comments to the following 

address: CMS, Office of Strategic 

Operations and Regulatory Affairs, 

Division of Regulations Development, 

Attention: Document Identifier/OMB 

Control Number: ll, Room C4–26–05, 

7500 Security Boulevard, Baltimore, 

Maryland 21244–1850. 

To obtain copies of a supporting 

statement and any related forms for the 

proposed collection(s) summarized in 

this notice, you may make your request 

using one of following: 

1. Access CMS’ website address at 

website address at https://www.cms.gov/ 

Regulations-and-Guidance/Legislation/ 

PaperworkReductionActof1995/PRAListing.html. 

FOR FURTHER INFORMATION CONTACT: 

William N. Parham at (410) 786–4669. 

SUPPLEMENTARY INFORMATION: 

Contents 

This notice sets out a summary of the 

use and burden associated with the 

following information collections. More 

detailed information can be found in 

each collection’s supporting statement 

and associated materials (see 

ADDRESSES). 

CMS–10494 Exchange Functions: 

Standards for Navigators and NonNavigator Assistance Personnel-CAC 

CMS–10773 Non-Quantitative 

Treatment Limitation Analyses and 

Compliance Under MHPAEA 

Under the PRA (44 U.S.C. 3501– 

3520), federal agencies must obtain 

approval from the Office of Management 

and Budget (OMB) for each collection of 

information they conduct or sponsor. 

The term ‘‘collection of information’’ is 

defined in 44 U.S.C. 3502(3) and 5 CFR 

1320.3(c) and includes agency requests 

or requirements that members of the 

public submit reports, keep records, or 

provide information to a third party. 

Section 3506(c)(2)(A) of the PRA 

requires federal agencies to publish a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension or reinstatement of an existing 

collection of information, before 

submitting the collection to OMB for 

approval. To comply with this 

requirement, CMS is publishing this 

notice. 

Information Collection 

1. Type of Information Collection 

Request: Revision of a currently 

approved collection; Title of 

Information Collection: Exchange 

Functions: Standards for Navigators and 

Non-Navigator Assistance PersonnelCAC; Use: Section 1321(a)(1) of the 

Affordable Care Act directs and 

authorizes the Secretary to issue 

regulations setting standards for meeting 

the requirements under title I of the 

Affordable Care Act, with respect to, 

among other things, the establishment 

and operation of Exchanges. Pursuant to 

this authority, regulations establishing 

the certified application counselor 

program have been finalized at 45 CFR 

155.225. In accordance with 

155.225(d)(1) and (7), certified 

application counselors in all Exchanges 

are required to be initially certified and 

recertified on at least an annual basis 

and successfully complete Exchange 

required training. Form Number: CMS– 

10494 (OMB control number: 0938– 

1205); Frequency: On Occasion; 

Affected Public: State, Local, or Tribal 

Governments, Private Sector (not-forprofit institutions); individuals or 

households; Number of Respondents: 

278,072; Total Annual Responses: 

278,072; Total Annual Hours: 918,024. 

For policy questions regarding this 

collection contact Evonne Muoneke at 

301–492–4402. 

2. Type of Information Collection 

Request: Extension of a currently 

approved collection; Title of 

Information Collection: NonQuantitative Treatment Limitation 

Analyses and Compliance Under 

MHPAEA; Use: The Paul Wellstone and 

Pete Domenici Mental Health Parity and 

Addiction Equity Act of 2008 

(MHPAEA) (Pub. L. 110–343) generally 

requires that group health plans and 

group health insurance issuers offering 

mental health or substance use disorder 

(MH/SUD) benefits in addition to 

medical and surgical (med/surg) 

benefits do not apply any more 

restrictive financial requirements (e.g., 

co-pays, deductibles) and/or treatment 

limitations (e.g., visit limits, prior 

authorizations) to MH/SUD benefits 

than those requirements and/or 

limitations applied to substantially all 

med/surg benefits. The Patient 

Protection and Affordable Care Act, 

Public Law 111–148, was enacted on 

March 23, 2010, and the Health Care 

and Education Reconciliation Act of 

2010, Public Law 111–152, was enacted 

on March 30, 2010. These statutes are 

collectively known as the ‘‘Affordable 

Care Act.’’ The Affordable Care Act 

extended MHPAEA to apply to the 

individual health insurance market. 

MHPAEA does not apply directly to 

small group health plans, although its 

requirements are applied indirectly in 

connection with the Affordable Care 

Act’s essential health benefit 

requirements. The Consolidated 

Appropriations Act, 2021 (the 

Appropriations Act) was enacted on 

December 27, 2020. The Appropriations 

Act amended MHPAEA, in part, by 

expressly requiring group health plans 

and health insurance issuers offering 

group or individual health insurance 

coverage that offer both med/surg 

benefits and MH/SUD benefits and that 

impose non-quantitative treatment 

limitations (NQTLs) on MH/SUD 

benefits to perform and document their 

comparative analyses of the design and 

application of NQTLs. Further, 

beginning 45 days after the date of 

enactment of the Appropriations Act, 

group health plans and health insurance 

issuers offering group or individual 

health insurance coverage must make 

their comparative analyses available to 

the Departments of Labor, Health and 

Human Services (HHS), and the 

Treasury or applicable state authorities, 

upon request. The Secretary of HHS is 

required to request the comparative 

analyses for plans that involve potential 

violations of MHPAEA or complaints 

regarding noncompliance with 

MHPAEA that concern NQTLs and any 

other instances in which the Secretary 

determines appropriate. The 

Appropriations Act also requires the 

Secretary of HHS to submit to Congress, 

and make publicly available, an annual 

report on the conclusions of the 

reviews. Form Number: CMS–10773 

(OMB control number: 0938–1393); 

Frequency: On Occasion; Affected 

Public: State, Local, or Tribal 

Governments, Private Sector; Number of 

Respondents: 250,137; Total Annual 

Responses: 36,461; Total Annual Hours: 

1,013,184. (For policy questions 


jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 86, No. 114 / Wednesday, June 16, 2021 / Notices 32051 

regarding this collection, contact Usree 

Bandyopadhyay at 410–786–6650.) 

Dated: June 10, 2021. 

William N. Parham, III, 

Director, Paperwork Reduction Staff, Office 

of Strategic Operations and Regulatory 

Affairs. 

[FR Doc. 2021–12583 Filed 6–15–21; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIDA– 

L Conflict SEP. 

Date: July 22, 2021. 

Time: 11:00 a.m. to 12:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Soyoun Cho, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

National Institute on Drug Abuse, NIH, 301 

North Stonestreet Avenue, Room 09C63, 

Bethesda, MD 20892, (301) 594–9460, 

Soyoun.cho@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: June 10, 2021. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–12623 Filed 6–15–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Investigator Initiated 

Program Project Applications (P01 Clinical 

Trial Not Allowed). 

Date: July 7, 2021. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F30A, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Ellen S. Buczko, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3F30, Rockville, MD 

20852, (240) 669–5028, ebuczko1@

niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: June 10, 2021. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–12622 Filed 6–15–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Eye Institute 

Special Emphasis Panel; BRAIN Initiative: 

New Concepts and Early-Stage Research for 

Recording and Modulation in the Nervous 

System (R21). 

Date: July 20, 2021. 

Time: 12:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Eye Institute, National 

Institutes of Health, Division of Extramural 

Research, 6700B Rockledge Drive, Suite 

3400, Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Brian Hoshaw, Ph.D., 

Designated Federal Official, National Eye 

Institute, National Institutes of Health, 

Division of Extramural Research, 6700B 

Rockledge Drive, Suite 3400, Bethesda, MD 

20892, 301–451–2020, hoshawb@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.867, Vision Research, 

National Institutes of Health, HHS) 

Dated: June 10, 2021. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–12625 Filed 6–15–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 


jbell on DSKJLSW7X2PROD with NOTICES